Associated Papers
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
Dey P et al.
Oncogene, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.
Page K et al.
Breast Cancer Research and Treatment, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer.
Berg T et al.
Neoplasia (new York, N.y.), 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.
Liu D et al.
Cancer Research Communications, 2025
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
De A et al.
Research Square, 2025
Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer.
Yao J et al.
Frontiers in Immunology, 2025
ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity.
Agaimy A et al.
Virchows Archiv : an International Journal of Pathology, 2024
Evaluation of whole genome sequencing utility in identifying driver alterations in cancer genome.
Nagashima T et al.
Scientific Reports, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type.
Pinheiro M et al.
Nature Communications, 2024
HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer.
Mishra R et al.
Molecular Carcinogenesis, 2024
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer.
Fasching PA et al.
Npj Breast Cancer, 2024
HER2 mutation as an emerging target in advanced breast cancer.
Bon G et al.
Cancer Science, 2024
Trans-activating mutations of the pseudokinase ERBB3.
Koivu MKA et al.
Oncogene, 2024
Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome.
Yang LP et al.
Cell Reports. Medicine, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.
Dey P et al.
International Journal of Biological Macromolecules, 2023
PD-L1 expression is regulated by ATP-binding of the ERBB3 pseudokinase domain.
Li Y et al.
Genes & Diseases, 2023
Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer.
Nguyen Hoang VA et al.
Molecular Oncology, 2023
HER3 Alterations in Cancer and Potential Clinical Implications.
Kilroy MK et al.
Cancers, 2022
Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer.
Zhang L et al.
Molecular Oncology, 2022
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer.
Lyu D et al.
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu, 2022
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
Berrino E et al.
Genome Medicine, 2022
Systematic investigation of the prognostic impact of clonal status of somatic mutations across multiple cancer types.
Cheng P et al.
Genomics, 2022
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing.
Kostecka A et al.
Npj Breast Cancer, 2022
Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients.
Shim H et al.
Annals of Translational Medicine, 2022
An effective strategy for ligand-mediated pulldown of the HER2/HER3/NRG1β heterocomplex and cryo-EM structure determination at low sample concentrations.
Trenker R et al.
Methods in Enzymology, 2022
Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
Yu H et al.
Frontiers in Oncology, 2022
Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface.
Diwanji D et al.
Nature, 2021
HER3 Mutations Affect Tumor Response to HER2-Targeted Therapies.
Unknown Author
Cancer Discovery, 2021
Mutant HER2 needs mutant HER3 to be an effective oncogene.
Trenker R et al.
Cell Reports. Medicine, 2021
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Hanker AB et al.
Cancer Cell, 2021
Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Huang CC et al.
Bmc Cancer, 2021
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ et al.
Cell Research, 2021
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A et al.
Cancer Medicine, 2021
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.
Abdel-Wahab R et al.
Scientific Reports, 2020
Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.
Elliott E et al.
Cancer Reports (hoboken, N.j.), 2020
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Lang GT et al.
Nature Communications, 2020
Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers.
Suzuki T et al.
Oncotarget, 2020
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S et al.
Breast Cancer Research : Bcr, 2020
ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications.
Jin W
Journal of Clinical Medicine, 2020